Recently, Prof. Chang Liu's team from the School of Life Science and Technology of the University of China published their latest research results “Photosensitive Biomimetic Nanomedicine-Mediated Recombination of Adipose Microenvironments for Antiobesity Therapy”. Dr. Mingming Song (now working at Anhui Medical University) and Li Wang (class of 2023) are the co-first authors of this paper, Dr. Mingming Song and Prof. Chang Liu are the co-corresponding authors, and China Pharmaceutical University (CPU) is the first author of the paper.
The core pathology of obesity lies in the vicious cycle of “metabolism-immunity” imbalance in adipose tissue. Due to poor targeting, insufficient controlled release and off-target toxicity, it is difficult for existing drugs to realize the synergistic effect of metabolic reprogramming and immune microenvironment regulation. In order to solve this problem, Prof. Chang Liu's group proposed a new strategy of “metabolism-immunity two-way synergistic regulation”, which can achieve synergistic effect of inflammation reduction and metabolism improvement by targeting the inhibition of macrophage M1 polarization and activation of PPARγ-mediated browning of white adipose tissue.
To this end, Prof. Chang Liu's group designed a novel red light responsive biomimetic nanoparticle drug delivery system, RSCP NPs, which can precisely target the inflammatory region of white adipose tissue by modifying the biofilm biomimetic carrier with adipose-targeting peptide, and achieve precise spatiotemporal controlled release of the drug by using the red light/pH dual-responsive system. The results showed that RSCP NPs could deliver astaxanthin and rosiglitazone to M1-type macrophages and white adipocytes, alleviate the low-grade inflammation of white adipose tissue and promote browning, and revealed the key node of “metabolism-immunity synergistic regulation” through histological analysis. This study provides a theoretical basis and practical foundation for the development and application of novel drug delivery systems in metabolic diseases.
This work was supported by the National Natural Science Foundation of China, the National Key Research and Development Program of China, the Natural Science Foundation of Jiangsu Province, the Natural Science Foundation of Anhui Province, the Natural Science Foundation of Xinjiang Uygur Autonomous Region, and the National Key Laboratory of Multi-targeted Natural Drugs of China Pharmaceutical University.
Full Text Link: https://doi.org/10.1002/adma.202417377
Diagram
